Atlas Trials

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Clinical trial NCT03766178 · UNKNOWN

Trial details

NCT number
NCT03766178
Sponsor
The First Affiliated Hospital of Zhengzhou University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Esophageal Squamous Cell Carcinoma
Start date
2021-09-01
Primary completion
2022-12-01
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.